Reassessment of Anti-Platelet Therapy Using an Individualized Strategy Based on Genetic Evaluation - RAPID GENE


The goal of the trial was to evaluate a strategy of rapid genotyping for the CYP2C19*2 allele with selective use of prasugrel (in carriers of the CYP2C19*2 allele) compared with standard therapy with clopidogrel (in noncarriers of the CYP2C19*2 allele) among patients undergoing percutaneous coronary intervention (PCI).